• Skip to main content

Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

STR001

Strekin AG Completes Phase 3 Clinical Study of STR001 to Restore Hearing in Patients with SSNHL

March 27, 2020

Strekin AG, a Swiss-based biopharmaceutical company focused on developing new treatments to reverse hearing loss, has completed its Phase 3 clinical trial of the investigational drug STR001 in patients with Sudden Sensorineural Hearing Loss (SSNHL).

According to the official study record (Source: ClinicalTrials.gov), the Status of Study NCT03331627, Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL, was changed from “Recruiting” to “Completed” on March 25, 2020. The actual completion date of the study was updated to February 6, 2020.

The purpose of this international, randomized, placebo-controlled, Phase 3 study, officially titled Phase III Multicenter, Double-blind, Placebo-controlled, Study Evaluating the Safety, and Efficacy of STR001 Treatment in Adults With Sudden Sensorineural Hearing Loss, was to evaluate the ability of STR001 to restore hearing in patients following a SSNHL event.

If the results are promising, STR001 could become the first approved treatment for SSNHL patients.

The previous update related to this clinical trial of STR001 was from over six months ago, on September 12, 2019. That is when Strekin AG announced in a press release the completion of patient recruitment for the study (which involved 165 patients).

Prior to that, the last change to the study record was almost a year ago, on April 10, 2019. That is when the study began recruiting patients, according to the official study page.

Source:

https://clinicaltrials.gov/ct2/show/NCT03331627?type=Intr


To get more exclusive (and early, early, early) hearing loss treatment-related news and updates, remember to join the mailing list for HearingLossTreatmentReport.com Email Updates. It’s free and you can unsubscribe at any time. One email per week – a simple list of links that were posted on the site during the previous 7 days. No spam or nonsense, completely private.


INVITATION TO RESEARCHERS, INDUSTRY PROFESSIONALS, and RESEARCH-SEEKING PATIENTS: For more information about how this site works, and how it automatically gathers all the latest and most relevant hearing loss treatment-related updates non-stop, 24/7… send an email to michael@urgentresearch.com and say hello.
– Michael S.


P.S. Here are three other hearing-related “treatment report” sites that might interest you:

  • TinnitusTreatmentReport.com
  • MenieresTreatmentReport.com
  • HyperacusisTreatmentReport.com

Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL [Completed]

March 25, 2020

https://clinicaltrials.gov/ct2/show/NCT03331627?type=Intr&cond=Hearing+Loss&lupd_s=03%2F27%2F2019&lupd_d=14&sort=nwst

Condition :   Acute Hearing Loss

Intervention :   Drug: STR001-IT and STR001-ER

Sponsor :   Strekin AG

Recruiting

Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL

NCT03331627

Mon, 06 Nov 2017 12:00:00 EST

Last Update Posted: 04/10/19 08:35AM

Powered by Urgent Research

Copyright © 2025 Urgent Research